Merck and Roche have joined forces to develop diagnostic assays for use with Merck's investigational cancer therapy portfolio.
The partnership will apply various technologies such as array and immunohistochemical (IHC/ISH) technologies.
Roche Diagnostics will offer validated, standardized assays for use in Merck’s clinical oncology programs.
Merck will also expand its use of Roche’s investigational AmpliChip p53 assay in its clinical programs to stratify and identify patients suitable for inclusion in ongoing/planned trial(s).
Merck Oncology Research senior vice president and head Gary Gilliland said the collaboration provides the company with access to diverse developmental and commercial diagnostic technologies that will facilitate the identification and monitoring of those patients most likely to respond to investigational cancer therapies.